REGENXBIO Sets Oct. 20 Investor Event Before Wet AMD Pivotal Data
Image
Rockville, Md. – October 12, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) will host a three-hour investor event on October 20, 2026 to review its wet age-related macular degeneration (wet AMD) gene therapy program, with topline pivotal data anticipated in the fourth quarter of 2026.
Event runs 1:00 p.m. to 4:00 p.m. ET in New York and online
The session will be held in person in New York and streamed by webcast. It will cover the clinical program for surabgene lomparvovec (sura-vec, ABBV-RGX-314), which REGENXBIO is developing in collaboration with AbbVie.
Management and five retina specialists to address commercial readiness
REGENXBIO management and retina specialists will discuss the treatment landscape, unmet need, the ATMOSPHERE and ASCENT pivotal trials, and the commercial readiness of sura-vec in wet AMD.
Five key opinion leaders are scheduled to appear: